Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Friday 26 April, 2019

AstraZeneca PLC

Result of AGM

RNS Number : 3119X
AstraZeneca PLC
26 April 2019
 

26 April 2019 17:45 BST

 

Results of Annual General Meeting held on 26 April 2019

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 12 were passed as special resolutions.

 


RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2018

 

1,002,386,773

99.96

381,361

0.04

1,002,768,134

76.44%

2,130,013

2

To confirm dividends

 

1,000,878,921

99.65

3,545,943

0.35

1,004,424,864

76.57%

474,696

3

To reappoint PricewaterhouseCoopers LLP as Auditor

 

1,003,208,151

99.90

1,002,311

0.10

1,004,210,462

76.55%

688,850

4

To authorise the Directors to agree the remuneration of the Auditor

 

1,002,479,345

99.82

1,794,309

0.18

1,004,273,654

76.56%

625,255

5a

To re-elect Leif Johansson as a Director

 

998,953,618

99.51

4,884,897

0.49

1,003,838,515

76.53%

1,060,758

5b

To re-elect Pascal Soriot as a Director

 

1,001,460,120

99.73

2,740,412

0.27

1,004,200,532

76.55%

699,226

5c

To re-elect Marc Dunoyer as a Director

 

997,205,236

99.31

6,915,112

0.69

1,004,120,348

76.55%

775,679

5d

To re-elect Geneviève Berger as a Director

 

993,018,194

99.77

2,314,964

0.23

995,333,158

75.88%

9,563,029

5e

To re-elect Philip Broadley as a Director

 

995,659,475

99.16

8,475,542

0.84

1,004,135,017

76.55%

761,114

5f

To re-elect Graham Chipchase as a Director

 

958,824,389

97.22

27,400,052

2.78

986,224,441

75.18%

18,671,390

5g

To re-elect Deborah DiSanzo as a Director

 

1,001,808,208

99.77

2,336,040

0.23

1,004,144,248

76.55%

751,639

5h

To re-elect Sheri McCoy as a Director

 

1,000,164,666

99.60

3,984,489

0.40

1,004,149,155

76.55%

746,732

5i

To elect Tony Mok as a Director

 

1,003,431,827

99.93

699,122

0.07

1,004,130,949

76.55%

764,625

5j

To re-elect Nazneen Rahman as a Director

 

1,001,687,441

99.76

2,413,171

0.24

1,004,100,612

76.55%

795,505

5k

To re-elect Marcus Wallenberg as a Director

 

908,178,624

90.44

96,025,641

9.56

1,004,204,265

76.55%

691,663

6

To approve the Annual Report on Remuneration for the year ended 31 December 2018

 

947,606,599

95.86

40,895,170

4.14

988,501,769

75.36%

16,392,056

7

To authorise limited political donations

 

977,701,447

97.87

21,290,398

2.13

998,991,845

76.16%

5,895,452

8

To authorise the Directors to allot shares

 

877,861,679

87.43

126,178,566

12.57

1,004,040,245

76.54%

853,485

9

To authorise the Directors to disapply pre-emption rights

 

990,106,053

98.92

10,841,253

1.08

1,000,947,306

76.31%

3,944,848

10

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments

 

979,272,055

97.83

21,681,201

2.17

1,000,953,256

76.31%

3,939,912

11

To authorise the Company to purchase its own shares

 

994,069,976

99.04

9,657,377

0.96

1,003,727,353

76.52%

1,164,722

12

To reduce the notice period for general meetings

 

905,789,402

90.67

93,205,859

9.33

998,995,261

76.16%

5,902,125

 

Issued capital

As at 24 April 2019, the number of issued shares of the Company was 1,311,759,192 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations



Gonzalo Viña

UK/Global

+44 203 749 5916

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Jennifer Hursit

UK/Global

+44 203 749 5762

Christina M Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharma - Cardiovascular; Metabolism

+44 203 749 5711

Nick Stone

BioPharma - Respiratory; Renal

+44 203 749 5716

Josie Afolabi

Other

+44 203 749 5631

Craig Marks

Finance; Fixed Income

+44 7881 615 764

Jennifer Kretzmann

Retail Investors; Corporate Access

+44 203 749 5824

US toll-free


+1 866 381 72 77




Adrian Kemp

Company Secretary

AstraZeneca PLC

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGPGUGCCUPBGQQ

a d v e r t i s e m e n t